Consistent with previous observations, we found that gefitinib plus si-UCA1 treatment inhibited tumor growth, but these changes were not observed in blank control and gefitinib plus negative control (NC)-treated tumors (Figure 3E, 3F). This evidence concerns the gene UCA1 and neoplasm.